BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.01 USD | -0.23% |
|
-2.07% | -14.23% |
| May. 16 | Everlasting momentum |  |
| May. 16 | Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Other Pharmaceuticals | -0.23% | -2.07% | -14.23% | -33.16% | -6.06% | 89.25B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- BMY Stock
- Charts Bristol-Myers Squibb Company
- Comparison Chart
